ClinicalTrials.gg
CompletedNCT04759768Updated Aug 13, 2024Results posted

Pharmacokinetic Evaluation of Intranasal Nalmefene

A Phase 1 interventional study of Nalmefene Hydrochloride and Nalmefene in Pharmacokinetics, sponsored by Opiant Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Opiant Pharmaceuticals Inc (part of Indivior Pharmaceuticals, Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is to determine the pharmacokinetics (how the body absorbs, breaks down and eliminates drug from your body) of nalmefene when given intranasally (IN;into the nose) compared to a dose of nalmefene when given intramuscularly (IM; into the muscle); to compare the blood levels of nalmefene when given IN to nalmefene when given IM; and to evaluate the safety and tolerability of nalmefene IN.

Read the detailed description

Open-label, randomized, 2-period, 2-treatment, 2-sequence, crossover study in 68 healthy volunteers. Subjects will be assigned to each of the 2 possible sequences. Each subject will receive 2 treatments during the 2 dosing periods: Intranasal (IN) dose of 3 mg nalmefene hydrochloride and intramuscular (IM) dose of 1.0 mg nalmefene, with a 4 day washout period between doses. Screening can occur up to 28 days before baseline admission, subjects will then stay in the inpatient facility for 7 days to complete the treatment phase of the study and will be discharged following completion of the discharge procedures at the end of the last period. Subjects will be called 3 to 5 days after discharge to inquire concerning Adverse Events (AEs) and concomitant medications since discharge.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Opiant Pharmaceuticals Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.

First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 55 years inclusive
  • ranging from 18 to 30 kg/m2, inclusive
  • Adequate venous access
  • Subjects must be non-smokers

Exclusion criteria

Exclusion Criteria:

  • History of disease
  • Significant trauma injury, major surgery, open within 30 days prior to screening
  • Following an abnormal diet 4 weeks prior to screening
  • Use of over the counter medications, dietary supplements, herbal products, vitamins or opioid analgesics 14 days before intervention
  • Use of enzyme altering drugs 30 days before intervention
  • Use of nasal products 28 days before intervention and throughout the study
  • Previous or current opioid, alcohol, or other drug dependence
  • Donated or received blood 30 days before intervention
  • Women who are pregnant or breastfeeding at screening
  • Women of unless surgically sterile or use effective
  • Current or recent upper respiratory tract infection
  • Allergic to nalmefene
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Intranasal Nalmefene

    Nalmefene hydrochloride nasal spray, 3mg, 1 spray

    Drug: Nalmefene Hydrochloride

  • Active comparator
    Intramuscular Nalmefene

    Nalmefene injection, 1mg, 1 injection

    Drug: Nalmefene

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Maximum concentration of plasma nalmefene comparing IN to IM

    Time frame: 48 hours

  2. Time to Maximum Plasma Concentration (Tmax)

    Time to maximum concentration of plasma nalmefene comparing IN to IM

    Time frame: 48 hours

  3. Area Under the Curve (AUC-inf)

    Area under the curve of plasma nalmefene comparing IN to IM

    Time frame: 48 hours

  4. Half-life (t1/2)

    Half life of plasma nalmefene comparing IN to IM

    Time frame: 48 hours

07

Results

Posted Aug 13, 2024

Participant flow

Complete

First Intervention (1 Day)
Participant flow — First Intervention (1 Day)
MilestoneIntranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal Nalmefene
Started3434
Completed3434
Not completed00
Washout (7 Days)
Participant flow — Washout (7 Days)
MilestoneIntranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal Nalmefene
Started3434
Completed3432
Not completed02
Withdrew: Withdrawal by subject01
Withdrew: Physician decision01
Second Intervention (1 Day)
Participant flow — Second Intervention (1 Day)
MilestoneIntranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal Nalmefene
Started3432
Completed3432
Not completed00

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)

Maximum concentration of plasma nalmefene comparing IN to IM

Time frame:
48 hours
Reported as:
Mean · ng/ml
Maximum Plasma Concentration (Cmax)
ng/mlIntranasal NalmefeneIntramuscular Nalmefene
Maximum Plasma Concentration (Cmax)12.2 ± 6.711.77 ± 1.18
PrimaryTime to Maximum Plasma Concentration (Tmax)

Time to maximum concentration of plasma nalmefene comparing IN to IM

Time frame:
48 hours
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax)
hoursIntranasal NalmefeneIntramuscular Nalmefene
Time to Maximum Plasma Concentration (Tmax)0.25 (0.0833 to 2)0.333 (0.117 to 18)
PrimaryArea Under the Curve (AUC-inf)

Area under the curve of plasma nalmefene comparing IN to IM

Time frame:
48 hours
Reported as:
Mean · hour*ng/mL
Area Under the Curve (AUC-inf)
hour*ng/mLIntranasal NalmefeneIntramuscular Nalmefene
Area Under the Curve (AUC-inf)41.5 ± 8.4517.0 ± 3.13
PrimaryHalf-life (t1/2)

Half life of plasma nalmefene comparing IN to IM

Time frame:
48 hours
Reported as:
Mean · hour
Half-life (t1/2)
hourIntranasal NalmefeneIntramuscular Nalmefene
Half-life (t1/2)11.4 ± 2.3710.6 ± 1.95

Adverse events

Collected over Subjects in the study from baseline to 7 days with a =3 to 5 day follow-up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intranasal Nalmefene0/66 (0%)0/66 (0%)42/66 (63.6%)
Intramuscular Nalmefene0/68 (0%)0/68 (0%)8/68 (11.8%)
Most frequent other events
Most frequent other events
EventIntranasal NalmefeneIntramuscular Nalmefene
nasal discomfortRespiratory, thoracic and mediastinal disorders37/660/68
dizzinessNervous system disorders4/661/68
headacheNervous system disorders3/664/68
nauseaGastrointestinal disorders2/664/68

Baseline characteristics

Age, Customized
Age, Customized(Participants)Intranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal NalmefeneTotal
Age 18 to 55 years old343468
Sex: Female, Male
Sex: Female, Male(Participants)Intranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal NalmefeneTotal
Female101828
Male241640
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Intranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal NalmefeneTotal
American Indian or Alaska native000
Asian123
Black or African American111223
Native Hawaiian or other specific islander101
White212041
Multiple000
Region of Enrollment
Region of Enrollment(participants)Intranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal NalmefeneTotal
United States343468
BMI
BMI(kg/m2)Intranasal Nalmefene Then Intramuscular NalmefeneIntramuscular Nalmefene Then Intranasal NalmefeneTotal
Mean26.58 ± 2.54025.60 ± 2.99626.09 ± 2.800
08

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2021, 3 months.

Results were first posted in Aug 2024, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2021
First posted
Feb 18, 2021
StartActual
Feb 8, 2021
Primary completionActual
May 17, 2021
CompletionActual
May 24, 2021
Results first posted
Aug 13, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04759768
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Feb 8, 2021
Primary completion
May 17, 2021
Completion
May 24, 2021
Results posted
Aug 13, 2024
Last update
Aug 13, 2024

Study contacts

Robert Bass, MD
principal investigator · Worldwide Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalmefene

Start the discussion